NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis

Միայն գրանցված օգտվողները կարող են հոդվածներ թարգմանել

Մուտք / Գրանցվել

Հղումը պահվում է clipboard- ում

ԿարգավիճակՀավաքագրում

Հովանավորներ

Medical University of Graz

Համագործակիցներ

Medical University Innsbruck

ԿԼԻՆԻԿԱԿԱՆ ՓՈՐՁԱՐԿՈՒՄ: NCT02801682

BioSeek: NCT02801682

Հիմնաբառեր

Վերացական

Invasive Candida infections are serious complications in immunocompromised patients including those undergoing treatment for cancer but occur also in patients treated in ICUs. Survival rate of invasive candidiasis is associated with early initiation of antifungal therapy (15% mortality rate for candidemic patients with antifungal therapy on day 0 related to the culture date of the first blood sample positive for yeasts compared to 41% for patients who received antifungal therapy on day 3). Up to date, no laboratory method or clinical decision rule is available for correct anticipation of invasive candidiasis which would avoid delays in appropriate antifungal therapy initiation. In clinical practice culture based methods (e.g. blood cultures) miss up to 50% of invasive candidiasis cases. Preemptive antifungal therapy is therefore often initiated in critically ill patients after Candida has been isolated from various non-sterile patient samples even without any sufficient evidence for invasive candidiasis. The disadvantages of this approach include over- and undertreatment of patients (up to 50% of candidemia cases are missed, and on the other hand 89% patients are treated unnecessarily), increased selective pressure for the development of antifungal resistance, potential risk of adverse drug reactions, and increased costs (expenses for antifungal therapy account for half of the antimicrobial medication budget in tertiary care hospitals). In addition, no survival benefit could be demonstrated by this strategy in ICU patients.

The aim of this study is to identify biological markers to anticipate or support the diagnosis of invasive candidiasis in ICU patients, to overcome current deficiencies in detection of invasive candidiasis and consequently to differentiate between Candida spp. colonization and invasive Candida infection. The investigators intend to examine time dependent courses of potential host and pathogen derived biomarkers as well as innate or acquired predispositions for invasive candidiasis; e.g. automated (1→3) ß- D- Glucan tests, DNA in serum blood samples, pathogen recognition receptors and serum markers like interleukin (IL)-1, IL-2, IL-6, IL-10, IL-12, IL-17A, IL-17F, IL-22, IL-23, Tryptophan, Kynurenine, composition of indigenous microbiota of gastrointestinal and lower respiratory tract and skin, and risk factors for invasive candidiasis like underlying diseases and treatments. The study should contribute to improved assessment of ICU patients at risk for invasive candidiasis and to improved diagnosis of invasive candidiasis in ICU patients. In clinical practice the reliable differentiation between infection and colonization will allow more targeted antifungal therapy leading to enhanced antifungal treatment initiation on the one hand (in cases of true invasive candidiasis) and to reduction of unnecessary antifungal treatments and treatment costs on the other hand.

Ամսաթվերը

Վերջին ստուգումը:	09/30/2019
Առաջինը ներկայացվում է:	06/08/2016
Մոտավոր գրանցումը ներկայացված է:	06/12/2016
Առաջին տեղադրումը:	06/15/2016
Վերջին թարմացումը ներկայացված է:	10/20/2019
Վերջին թարմացումը տեղադրված է:	10/22/2019
Ուսումնասիրության իրական մեկնարկի ամսաթիվը:	05/31/2016
Նախնական ավարտման նախնական ամսաթիվը:	09/30/2020
Ուսումնասիրության ավարտի գնահատման ամսաթիվը:	09/30/2020

Վիճակ կամ հիվանդություն

Invasive Candidiasis

Փուլ

Arm խմբերը

Արմ	Միջամտություն / բուժում
Healthy Controls
Invasive Candidiasis
Bacterial Sepsis (Bacteremia)
ICU patients without infectious disease

Իրավասության չափանիշներ

Ուսման իրավունք ունեցող դարաշրջանները	18 Years Դեպի 18 Years
Ուսումնասիրության իրավունք ունեցող սեռերը	All
Նմուշառման մեթոդ	Non-Probability Sample
Ընդունում է առողջ կամավորներ	Այո
Չափանիշներ	ad 1: Inclusion Criteria: -subjects without any evidence of current or chronic infectious diseases Exclusion Criteria: - Clinical or radiological or laboratory evidence of current infectious disease (temperature >38°C, elevated CRP >5mg/dl, leukocytosis >11400, elevated neutrophiles) - antifungal therapy within 8 weeks prior to inclusion - immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc) - active haematooncological diseases - HIV positivity ad 2: Inclusion criteria: -Patients with invasive Candidias/Candida sepsis as defined in recent EORTC/MSG definitions. Exclusion criteria: - glucocorticoid treatment with prednisone equivalent of ≥20mg/d - inherited neutrophil deficiency - absolute neutrophil count of ≤500cells/mm3 - antifungal therapy within 8 weeks prior to inclusion - immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d, methotrexate, azathioprin etc) - active hematooncological disease - HIV positivity ad 3: Inclusion criteria: -ICU patients with sepsis and proven bacteremia (Staph. aureus or E. coli) Exclusion criteria: - Antifungal therapy within 8 weeks prior to inclusion - immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d, methotrexate, azathioprin etc) - active hematooncological disease HIV positivity ad 4: Inclusion criteria: -ICU patients without invasive candidiasis as defined above, without bacteremia and without clinical and laboratory markers of infection(e.g. intubated and mechanically ventilated patients with stroke or CPR) Exclusion criteria: - Clinical or radiological or laboratory evidence of current infectious disease (temperature >38°C, elevated CRP >5mg/dl, leukocytosis >11400, elevated neutrophiles) - antifungal therapy within 8 weeks prior to inclusion - immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc) - active haematooncological diseases - HIV positivity

Արդյունք

Արդյունքների առաջնային միջոցառումներ

1. Biomarkers indicating or excluding invasive Candidiasis [through study completion, an average of 2 years]

Automated (1→3) ß- D- Glucan tests (pg/ml) DNA in serum blood samples (quantity and sequences) pathogen recognition receptors (% of cells as assessed by FACS analysis) serum markers like IL-1, IL-2, IL-6, IL-10, IL-12, IL-17A, IL-17F, IL-22, IL-23, Tryptophan, Kynurenine (quantity) composition of indigenous microbiota of gastrointestinal and lower respiratory tract and skin (comparison of detection rates and abundances of different classes or genera)

Արդյունքների երկրորդական միջոցներ

1. Risk factors for Invasive Candidiasis [through study completion, an average of 2 years]

Risk factors as described in previous literature, e.g. Eggimann, Lancet Infect Dis 2003; 3: 685-702

NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis

Հիմնաբառեր

տրիպտոֆան

candidiasis invasive

կանդիդոզ

սեպսիս

չարորակ ուռուցք

glucan

1 3 glucan

հակասնկային